46 per cent of patients saw no MS progression five years after receiving AHSCT treatment
New research from Dr Paolo Muraro, of the Department of Medicine at Imperial College London and his colleagues recently reported further evidence of autologous hematopoietic stem cell transplantation (AHSCT) as an effective treatment for multiple sclerosis (MS)...Read more - http://www.ms-uk.org/46-cent-patients-s ... ent-010317
46 per cent of patients saw no MS progression five years...
46 per cent of patients saw no MS progression five years...
MS-UK - http://www.ms-uk.org/
Re: 46 per cent of patients saw no MS progression five years
Since approximately 70% of those with MS do well regardless of treatment(s)/diet/exercise, I am not sure if this is a good result or not. That is the problem with any kind of treatment(s) - you just never really know if it/they are working or not.
Re: 46 per cent of patients saw no MS progression five years...
2019 Jun 24
Postgraduate Course, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612973/
Abstract
Autologous hematopoietic stem cell transplantation (AHSCT) is established as a standard of care for diseases ranging from hematological malignancies to other neoplastic pathologies and severe immunological deficiencies. In April 1995, our group performed the first AHSCT in progressive multiple sclerosis (MS). Since then, a plethora of studies have been published with encouraging but controversial results. Major challenges in the field include appropriate patient selection, improvements in AHSCT procedure, and timing of this treatment modality. Beyond AHSCT, several new intravenous or oral agents have been developed and approved over the last 20 years in MS. The emergence of multiple effective therapies for MS has created a challenging scenario for both treating physicians and patients. Novel cell-based therapies other than AHSCT are also currently investigated in MS patients with promising results. Our review is aimed at summarizing state-of-the-art knowledge on basic principles and results of AHSCT in MS and its role compared to novel agents.
Postgraduate Course, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612973/
Abstract
Autologous hematopoietic stem cell transplantation (AHSCT) is established as a standard of care for diseases ranging from hematological malignancies to other neoplastic pathologies and severe immunological deficiencies. In April 1995, our group performed the first AHSCT in progressive multiple sclerosis (MS). Since then, a plethora of studies have been published with encouraging but controversial results. Major challenges in the field include appropriate patient selection, improvements in AHSCT procedure, and timing of this treatment modality. Beyond AHSCT, several new intravenous or oral agents have been developed and approved over the last 20 years in MS. The emergence of multiple effective therapies for MS has created a challenging scenario for both treating physicians and patients. Novel cell-based therapies other than AHSCT are also currently investigated in MS patients with promising results. Our review is aimed at summarizing state-of-the-art knowledge on basic principles and results of AHSCT in MS and its role compared to novel agents.
https://www.eboro.cz
Re: 46 per cent of patients saw no MS progression five years...
2020 Jun 2
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Can Multiple Sclerosis Be Cured? A Case of Highly Active Relapsing Multiple Sclerosis Treated With Autologous Hematopoietic Stem-Cell Transplantation 13 Years Ago
https://pubmed.ncbi.nlm.nih.gov/32570177/
Abstract
A 26-year-old man, with five years of highly active deteriorating relapsing multiple sclerosis (MS), unresponsive to conventional therapy, was treated with autologous hematopoietic stem-cell transplantation (AHSCT) 13 years ago. Since then the patient had no clinical or neuroradiological disease activity and disability progression was halted. Repeated analysis of CSF revealed reduced levels of inflammatory biomarkers and the neurofilament light protein level was normalized indicating no further axonal degeneration. The patient is socio-economic independent, is working full time, and has become a father. Measures of quality of life and cognition did not indicate further deterioration. Long-term follow-up has not shown any signs of active disease suggesting that AHSCT may be a cure for MS.
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Can Multiple Sclerosis Be Cured? A Case of Highly Active Relapsing Multiple Sclerosis Treated With Autologous Hematopoietic Stem-Cell Transplantation 13 Years Ago
https://pubmed.ncbi.nlm.nih.gov/32570177/
Abstract
A 26-year-old man, with five years of highly active deteriorating relapsing multiple sclerosis (MS), unresponsive to conventional therapy, was treated with autologous hematopoietic stem-cell transplantation (AHSCT) 13 years ago. Since then the patient had no clinical or neuroradiological disease activity and disability progression was halted. Repeated analysis of CSF revealed reduced levels of inflammatory biomarkers and the neurofilament light protein level was normalized indicating no further axonal degeneration. The patient is socio-economic independent, is working full time, and has become a father. Measures of quality of life and cognition did not indicate further deterioration. Long-term follow-up has not shown any signs of active disease suggesting that AHSCT may be a cure for MS.
https://www.eboro.cz